BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 34143193)

  • 1. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
    JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
    JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.
    Blanchard P; Garden AS; Gunn GB; Rosenthal DI; Morrison WH; Hernandez M; Crutison J; Lee JJ; Ye R; Fuller CD; Mohamed AS; Hutcheson KA; Holliday EB; Thaker NG; Sturgis EM; Kies MS; Zhu XR; Mohan R; Frank SJ
    Radiother Oncol; 2016 Jul; 120(1):48-55. PubMed ID: 27342249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
    Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
    Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.
    Li Y; Guan X; Xing X; Hu C
    Head Neck; 2024 Apr; ():. PubMed ID: 38591178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
    Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
    Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy.
    Chang CL; Lin KC; Chen WM; Shia BC; Wu SY
    J Thorac Oncol; 2024 May; 19(5):818-828. PubMed ID: 38154513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy.
    Alterio D; D'Ippolito E; Vischioni B; Fossati P; Gandini S; Bonora M; Ronchi S; Vitolo V; Mastella E; Magro G; Franco P; Ricardi U; Krengli M; Ivaldi G; Ferrari A; Fanetti G; Comi S; Tagliabue M; Verri E; Ricotti R; Ciardo D; Jereczek-Fossa BA; Valvo F; Orecchia R
    Acta Oncol; 2020 May; 59(5):541-548. PubMed ID: 32090645
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).
    Mi JL; Meng YL; Wu HL; Cao YL; Zhang B; Pan YF; Zhou YY; Fan JF; Liao SF; Qin XL; Yao DC; Jiang W
    Strahlenther Onkol; 2020 Mar; 196(3):270-279. PubMed ID: 31748837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
    Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
    J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical outcomes of helical tomotherapy/intensity-modulated proton therapy combination in nasopharynx cancer.
    Park SG; Ahn YC; Oh D; Noh JM; Ju SG; Kwon D; Jo K; Chung K; Chung E; Lee W; Park S
    Cancer Sci; 2019 Sep; 110(9):2867-2874. PubMed ID: 31237050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
    Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
    Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
    Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx.
    Nam H; Ahn YC; Yang K; Oh D; Noh JM
    Cancer Res Treat; 2022 Jan; 54(1):96-108. PubMed ID: 33781049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
    Yu NY; DeWees TA; Voss MM; Breen WG; Chiang JS; Ding JX; Daniels TB; Owen D; Olivier KR; Garces YI; Park SS; Sarkaria JN; Yang P; Savvides PS; Ernani V; Liu W; Schild SE; Merrell KW; Sio TT
    Clin Lung Cancer; 2022 Dec; 23(8):e526-e535. PubMed ID: 36104272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.